Market Capitalization

Dubai's office market is booming as AHS Tower sells out during development, setting a new benchmark for wellness-focused, luxury commercial spaces.

China’s pioneering EV charging firm NaaS faces a delisting threat from Nasdaq, battling not just low market value but also negative equity and major losses.

First Horizon's financial and credit chiefs will present at a key conference. We dive into their strategy amid industry headwinds and strong 2025 results.

Malaysian solar firm FGL faces delisting after a reverse stock split, meant to save its listing, backfired and wiped out its public share float.

Amid soaring demand, Cleanroom Film & Bags adds a high-speed production line, reinforcing the supply chains for vital medical and semiconductor industries.

Korean brand Laka brings its gender-neutral philosophy to Sephora, betting that US consumers are ready for beauty without rigid rules or boundaries.

F&G Annuities & Life declared its quarterly dividend, offering a sign of stability even as a recent earnings report and stock drop raise questions.

The chemical giant's dramatic dividend cut ends a 14-year growth streak, raising questions about sector health and long-term investor returns.

Seagate retires $600M in debt for cash and stock. A strategic move to fortify its balance sheet, but what does the share dilution mean for investors?

A federal court ruling against Corcept Therapeutics clears a key legal hurdle for Teva's generic Cushing's syndrome drug, rattling investors.

Facing delisting, the Singaporean tech firm enacts a 1-for-20 reverse split. Is it a lifeline or a sign of deeper financial troubles ahead?

Element Biosciences unveils VITARI, a high-throughput benchtop sequencer promising a $100 whole genome, challenging market giants and democratizing genomics.

As it heads to key conferences, Orchestra BioMed is pitching its novel pacemaker-based hypertension treatment and a unique drug-eluting balloon.

Clene Inc. faces investors with promising data for ALS and MS, but a looming cash crunch makes its upcoming conference a critical test of survival.

After a volatile market debut, the supersonic flight company hits the NYSE, signaling a new era for high-speed testing and air-launch services.

New five-year data for SYFOVRE shows a significant delay in geographic atrophy progression, offering long-term hope but also sparking clinical debate.

At a major scientific conference, Seer Inc.'s Proteograph platform is taking center stage, promising deeper insights into Alzheimer's and heart disease.

Specialist asset manager Sprott Inc. leverages a volatile market and geopolitical tensions, riding a precious metals boom to record profits and AUM growth.

After a major pipeline pivot, Keros Therapeutics faces investors with a new lead drug, a fortified balance sheet, and a high-stakes strategy to prove.

With a high-yield but unstable dividend, Brandywine's Q1 earnings will reveal its strategy for navigating the challenging urban office market.